Font size
WorksheetsInsulin Launch Quiz
Total questions: 18
Worksheet time: 28mins
Enter your Employee Code. (Please recheck before submitting)
Please mention Region Name (For RM) Zone NAme (For Zonal Manager)
Designation
Insulins Degludec and glargine administered once daily in combination with OADs provided ________long-term glycemic control in insulin-naive patients with type 2 Diabetes. (BEGIN study)
Lowest
Better
Similar
Select the correct Conclusion statement for DEVOTE Study
Among patients with type 2 diabetes at high risk for cardiovascular events, Degludec was noninferior to glargine with respect to the incidence of major cardiovascular events.
Degludec was noninferior to NPH with respect to the incidence of major cardiovascular events.
Aspart was noninferior to Degludec with respect to the incidence of major cardiovascular events.
Aspart was superior Over Short acting Insulin
INSTRIDE 1 And 2 talks about which 3 comparative parameters between Reference and Biosimilar Insulin Glargine
HbA1c Reduction
Anytime Hypoglycemia
Weight Gain
Amount of Dose needed for similar physiological response
As per EDITION 3: Gla-300 is as effective as Gla-100 in reducing HbA1c in insulin-naïve people with type 2 diabetes.
True
False
Full Form of "MAGE"
Major Adverse Glycemic Event
Mean Amplitude of Glycemic Excursions
Mean Amplitude for Glycemic Elimination
Major Amplitude of Glycemic Elimination
Selects missing Steps of Insulin Release
1. Glucose enter the Beta cell via GLUT 2
2. Glucose (Glucose-6-Kinase) converts to ATP - Glycolysis
3. ATP Sensitive K+ Channel closed
4. Membrane Depolarisation
5. ________________________
6. Insulin released from Insulin vesicles (Exocytosis).
ATP opens ATP sensitive potassium channel
Voltage Gated Ca++ Channel will Open, Ca++ enters
Voltage gated Ca++ channel will close
Glucagon will reach to Blood
Composition of "Humalog Mix 25"
Lispro 25 + Regular Human protamine Insulin (NPH) 75
Lispro 25 + Lispro Protamine suspension 75
Lispro 25 + Degludec
Lispro 25 + Glargine
rDNA Insulin in Nobeglar obtained from which Micro-organism
saccharomyces cerevisiae
Pischia Pastoris
Saccharomyces pastorianus
E. Coli
Select Right Option: Basal supported oral therapy (BOT)
Addition of one or two bolus insulin to basal insulin ± OADs
Addition of basal insulin to existing OADs
Once daily / twice daily premixed insulin therapy
Addition of bolus insulin before each meal to basal insulin ± OADs
What is the difference between Biosimilar Insulin Glargine and Reference Insulin Glargine?
Biosimilar Insulin Glargine is less effective
Biosimilar Insulin Glargine has a different chemical composition
Biosimilar Insulin Glargine is as Quality, Efficacy and Safety as Reference Insulin Glargine
None of the above
Is Biosimilar Insulin Glargine interchangeable with Reference Insulin Glargine?
Yes, it is interchangeable
No, it is not interchangeable
It depends on the individual patient
Which of the following statements about biosimilar Insulin Glargine is true? (more than 1 correct answer)
Biosimilar Insulin Glargine has a similar mechanism of action as the reference product, Lantus.
The clinical efficacy and safety of biosimilar Insulin Glargine have been demonstrated in clinical trials.
Biosimilar Insulin Glargine is manufactured using the same process and quality standards as the reference product.
What is the recommended starting dose of biosimilar Insulin Glargine for patients with type 2 diabetes?
0.2 units/kg/day
0.5 units/kg/day
1 units/kg/day
1.5 units/kg/day
Biosimilar Insulin Glargine has been shown to be clinically equivalent to its reference product in which of the following areas? (INSTRIDE 3)
Glycemic control
Hypoglycemic Incidence
Immunogenicity
All of the above
What are the Reason for Unexplained Hypoglycemia
Lipodystrophy
Insulin Storing Condition
Insulin Cold chain not managed
Wrong Insulin injection technique
All of the above
